SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Big fish with a dollar badge wants to eat small fish
Mergers & acquisitions
Concentra Buys Beleaguered iTeos at Slight Discount
In May, biotech iTeos Therapeutics decided to close down after being abandoned by GSK over the disappointing mid-stage performance of its anti-TIGIT antibody belrestotug.
July 22, 2025
 · 
2 min read
 · 
Tristan Manalac
IN PARTNERSHIP WITH ECLIPSEBIO
Why Countries Are Racing To Build mRNA Factories While America Hesitates on Next-Gen Vaccines
In this episode presented by Eclipsebio, BioSpace’s head of insights Lori Ellis continues the discussion on mRNA and srRNA with Andy Geall of Replicate Bioscience and Alliance for mRNA Medicines and Pad Chivukula of Arcturus Therapeutics.
July 22, 2025
 · 
1 min read
 · 
Lori Ellis
Illustration of man waving big white flag, surreal abstract concept
Duchenne muscular dystrophy
Sarepta Concedes to FDA Request, Suspends US Shipments of Elevidys
After initially refusing to suspend Elevidys distribution after two deaths, Sarepta has now given in to the FDA’s request, noting the need to maintain a good working relationship with the regulator.
July 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Searching for investments for a startup. Fundraising campaigns. Accumulation of funds. Search for investors and lending. New space race. A promising project
Funding
Avalyn Pharma Adds $100M Series D for Inhaled Pulmonary Fibrosis Drugs
The company is pushing inhaled versions of common oral drugs with the hope of avoiding severe side effects.
July 22, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Courtesy Boston Pharmaceuticals
C-suite
Sophie Kornowski: From Medicine Taste-Tester to Data-Driven Dealmaker
What will Boston Pharmaceuticals CEO Sophie Kornowski do now that the company is selling off its pipeline and winding down operations? Whatever it is, data will take her there.
July 22, 2025
 · 
5 min read
 · 
Annalee Armstrong
Biogen’s headquarters in Massachusetts
Manufacturing
Biogen Commits $2B To Expand US Drug Production Amid Tariff Talk
The biotech is planning to expand antisense oligonucleotide capabilities and infrastructure on campuses that already produce drugs such as the ALS therapy Qalsody.
July 21, 2025
 · 
2 min read
 · 
Nick Paul Taylor
A brick building with the sign Food and Drug Administration on the entrance
Regulatory
FDA’s CDER Gets New Chief in Biopharma Veteran George Tidmarsh
Tidmarsh, an adjunct professor at Stanford’s medical school, brings decades of industry experience to the table. Serving as director of the Center for Drug Evaluation and Research will be his first government position.
July 21, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
3d rendering of a red and silver realistic model of a retro rocket stands crashed into a wooden desk on a blue background. Failed launch. Technological progress. Technical mistake.
Immunology and inflammation
Roche Flunks Phase III Trial in COPD, Falling Further Behind Dupixent
The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly lower disease exacerbation rates versus placebo in patients with chronic obstructive pulmonary disease.
July 21, 2025
 · 
2 min read
 · 
Tristan Manalac
a row of red down arrows and green up arrows. hand choose arrow. the concept of inflation. the concept of taking profit or increasing income. different options. difference of direction icon, business, arrow, arrows, marketing, green, success, red, sign, graph, investment, chart, corporate, growth, financial, currency, market, profit, exchange, stock, economic, motion, forecast, cursor, inflation, recession, investor, pointer, download, trend, loss, vertical, progress, statistic, direction, symbol, crisis, down, downward, increase, lift, pointing, previous, raise, two, up, upward, upwards, vote
Adcomms
Otsuka, Lundbeck Fail To Sway Adcomm on Rexulti Combo for PTSD
Otsuka and Lundbeck’s data are insufficient to establish significant efficacy of Rexulti plus sertraline in PTSD, according to the FDA’s outside experts.
July 21, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS